SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.78-0.3%3:32 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LarryS who wrote (9367)3/24/1999 9:17:00 PM
From: Bluegreen  Read Replies (1) of 17367
 
Larry, this disease IS less deadly than expected from expected amount of enrollees isn't that why we are at 370 and just now "close"? Ask yourself what are the chances that you pick at random 26 kids with Meningo. and 25 out of 26 don't die. Now you look at the physical characteristics of the dead one and ask yourself how many of these are going to be in TREATED group of PhaseIII. Now since most in trial are Brits, are your chances greater or less of getting person with those characteristics? You see in my opinion the only persons that might be dying in the treated group in Phase III have to have at least as bad physical characteristics as the one dead in Phase II. The only thing just as deadly besides being in placebo group is Meningo. with those characteristics of person in PhaseII that died in my opinion. George, Murphy corrected himself tonight and said it was 130 not 125!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News